Actively Recruiting
Relationship Between Different Administration Regimens of Ceftazidime/Avibactam and Clinical Outcomes
Led by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Updated on 2024-07-30
140
Participants Needed
1
Research Sites
56 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Ceftazidime/avibactam (CAZ/AVI) is a new β-lactam drug, which has good antibacterial effect against carbapenem resistant enterobacter. However, previous studies found that CAZ/AVI had a low PK/PD compliance rate after the recommended dose of the drug instructions.Therefore, this study was intended to explore the clinical efficacy of different administration schedules of CAZ/AVI for patients with severe infection, and further analyze the correlation between CAZ/AVI PK/PD parameters and clinical efficacy and adverse reactions.
CONDITIONS
Official Title
Relationship Between Different Administration Regimens of Ceftazidime/Avibactam and Clinical Outcomes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Infection with multiple-resistant bacteria sensitive to ceftazidime/avibactam
- Received intravenous infusion of ceftazidime/avibactam
You will not qualify if you...
- Allergy to ceftazidime/avibactam
- Blood sample could not be collected
- Pregnant or lactating
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Intensive Care Unit, Drum Tower Hospital
Nanjing, Jiangsu, China, 210009
Actively Recruiting
Research Team
Y
Ying Xu, Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here